Leerink Swann maintained Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) on Tuesday, July 21 with "Outperform" rating. The business is expected to announce its next quarterly earnings results on Tuesday, November 21st. Teva named Kåre Schultz as President and CEO. The company beat the analyst EPS Estimate with the difference of $0.03. Zacks' sales averages are a mean average based on a survey of analysts that cover Teva Pharmaceutical Industries Limited. The value of the total investment in Teva Pharmaceutical Industries went from $11,751,000 to $9,479,000 decreasing 19.3% quarter to quarter. The business had revenue of $5.69 billion for the quarter, compared to analysts' expectations of $5.72 billion. Therefore 21% are positive.
TEVA stock was up 20% as of Monday afternoon, but is down 47% year-to-date. Annual EPS Growth of past 5 years is -53.00%.
Several analysts have issued reports on TEVA shares. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has declined 41.70% since September 11, 2016 and is downtrending. The firm has "Hold" rating given on Monday, August 28 by Cowen & Co. Jefferies has "Hold" rating and $3300 target.
A number of other analysts have also recently commented on the stock.
Hills Bank & Trust Company, which manages about $284.64M US Long portfolio, upped its stake in Intercontinental Exchange Inc (NYSE:ICE) by 55,957 shares to 69,930 shares, valued at $3.95 million in 2016Q4, according to the filing. PGGM Investments lifted its stake in shares of Teva Pharmaceutical Industries Limited by 12.0% in the second quarter.
In addition, Mr. Schultz will receive sign-on equity awards of roughly $40 million, depending on the performance of the firm, paid over a five-year period, the company said. Mizuho Securities Usa Inc acquired 60,200 shares as Teva Pharmaceutical Inds Ltd (TEVA)'s stock declined 15.11%. Meanwhile, top losers in the sector included Vonage Holdings Corp. The company has Beta Value of 0.64 and ATR value of 0.91. Teva Pharmaceutical Industries declared a dividend payable on Thursday the 14th of September 2017. Institutional investors and hedge funds own 56.87% of the company's stock. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Shares of Teva were last seen up about 18% at $18.32, with a consensus analyst price target of $25.00 and a 52-week range of $15.22 to $52.66. The short-interest ratio increased to 1.0 and the short interest percentage is 0.04% as of August 15.
That revealed cracks in Teva's strategy of aggressive acquisitions that made it into a pharmaceutical giant but also saddled it with a debt burden that is nearly twice its market value. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and worldwide trademark & copyright laws. (MYL - Free Report) and Momenta Pharmaceuticals, Inc.